dc.contributor.author
Lu, Yong-Ping
dc.contributor.author
Wu, Hong-Wei
dc.contributor.author
Zhu, Ting
dc.contributor.author
Li, Xi -Tong
dc.contributor.author
Zuo, Jiao
dc.contributor.author
Hasan, Ahmed A.
dc.contributor.author
Reichetzeder, Christoph
dc.contributor.author
Delic, Denis
dc.contributor.author
Yard, Benito
dc.contributor.author
Klein, Thomas
dc.date.accessioned
2023-01-19T08:35:31Z
dc.date.available
2023-01-19T08:35:31Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/37701
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-37416
dc.description.abstract
Background
Sodium glucose cotransporter 2 (SGLT2) inhibitors originally developed for the treatment of type 2 diabetes are clinically very effective drugs halting chronic kidney disease progression. The underlying mechanisms are, however, not fully understood.
Methods
We generated single-cell transcriptomes of kidneys from rats with 5/6 nephrectomy before and after SGLT2 inhibitors treatment by single-cell RNA sequencing.
Findings
Empagliflozin treatment decreased BUN, creatinine and urinary albumin excretion compared to placebo by 39.8%, 34.1%, and 55%, respectively (p < 0.01 in all cases). Renal interstitial fibrosis and glomerulosclerosis was likewise decreased by 51% and 66.8%; respectively (p < 0.05 in all cases). 14 distinct kidney cell clusters could be identified by scRNA-seq. The polarization of M2 macrophages from state 1 (CD206-CD68- M2 macrophages) to state 5 (CD206+CD68+ M2 macrophages) was the main pro-fibrotic process, as CD206+CD68+ M2 macrophages highly expressed fibrosis-promoting genes and can convert into fibrocytes. Empagliflozin remarkably inhibited the expression of fibrosis-promoting (IFG1 and TREM2) and polarization-associated genes (GPNMB, LGALS3, PRDX5, and CTSB) in CD206+CD68+ M2 macrophages and attenuated inflammatory signals from CD8+ effector T cells. The inhibitory effect of empagliflozin on CD206+CD68+ M2 macrophages polarization was mainly achieved by affecting mitophagy and mTOR pathways.
Interpretation
We propose that the beneficial effects of empagliflozin on kidney function and morphology in 5/6 nephrectomyiced rats with established CKD are at least partially due to an inhibition of CD206+CD68+ M2 macrophage polarization by targeting mTOR and mitophagy pathways and attenuating inflammatory signals from CD8+ effector T cells.
Fundings
A full list of funding bodies that contributed to this study can be found in the Acknowledgements section.
en
dc.format.extent
11 Seiten
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Non-diabetic kidney disease
en
dc.subject
SGLT2 inhibitor
en
dc.subject
Macrophage-myofibroblast transition
en
dc.subject
Polarization
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::615 Pharmakologie, Therapeutik
dc.title
Empagliflozin reduces kidney fibrosis and improves kidney function by alternative macrophage activation in rats with 5/6-nephrectomy
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
113947
dcterms.bibliographicCitation.doi
10.1016/j.biopha.2022.113947
dcterms.bibliographicCitation.journaltitle
Biomedicine & Pharmacotherapy
dcterms.bibliographicCitation.volume
156
dcterms.bibliographicCitation.url
https://doi.org/10.1016/j.biopha.2022.113947
refubium.affiliation
Biologie, Chemie, Pharmazie
refubium.affiliation.other
Institut für Pharmazie
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.isPartOf.eissn
1950-6007
refubium.resourceType.provider
WoS-Alert